ALC Quote, Financials, Valuation and Earnings

Novartis AG has a net margin of 14.15% compared to Alcon's net margin of 26.48%. Alcon's return on equity of 5.25% beat Novartis AG's return on equity of 30.96%.

Alcon has a consensus price target of $105.79, signalling upside risk potential of 22.73%. On the other hand Novartis AG has an analysts' consensus of $112.64 which suggests that it could fall by -5.7%. Given that Alcon has higher upside potential than Novartis AG, analysts believe Alcon is more attractive than Novartis AG.

Alcon has a beta of 0.948, which suggesting that the stock is 5.206% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.595, suggesting its less volatile than the S&P 500 by 40.528%.

Alcon has a quarterly dividend of $0.34 per share corresponding to a yield of 0.4%. Novartis AG offers a yield of 3.34% to investors and pays a quarterly dividend of $3.99 per share. Alcon pays 12.77% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are smaller than Novartis AG quarterly revenues of $13.6B. Alcon's net income of $350M is lower than Novartis AG's net income of $3.6B. Notably, Alcon's price-to-earnings ratio is 38.31x while Novartis AG's PE ratio is 18.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.32x versus 4.52x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of 14.15% compared to Alcon's net margin of 0.11%. Alcon's return on equity of 5.25% beat BeOne Medicines's return on equity of -11.54%.

Alcon has a consensus price target of $105.79, signalling upside risk potential of 22.73%. On the other hand BeOne Medicines has an analysts' consensus of $331.97 which suggests that it could grow by 23.12%. Given that BeOne Medicines has higher upside potential than Alcon, analysts believe BeOne Medicines is more attractive than Alcon.

Alcon has a beta of 0.948, which suggesting that the stock is 5.206% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.143%.

Alcon has a quarterly dividend of $0.34 per share corresponding to a yield of 0.4%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alcon pays 12.77% of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend. Alcon's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are larger than BeOne Medicines quarterly revenues of $1.1B. Alcon's net income of $350M is higher than BeOne Medicines's net income of $1.3M. Notably, Alcon's price-to-earnings ratio is 38.31x while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.32x versus 6.92x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 14.15% compared to Alcon's net margin of --. Alcon's return on equity of 5.25% beat Roche Holding AG's return on equity of 23.8%.

Alcon has a consensus price target of $105.79, signalling upside risk potential of 22.73%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 12.34%. Given that Alcon has higher upside potential than Roche Holding AG, analysts believe Alcon is more attractive than Roche Holding AG.

Alcon has a beta of 0.948, which suggesting that the stock is 5.206% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.459, suggesting its less volatile than the S&P 500 by 54.134%.

Alcon has a quarterly dividend of $0.34 per share corresponding to a yield of 0.4%. Roche Holding AG offers a yield of 3.36% to investors and pays a quarterly dividend of $1.39 per share. Alcon pays 12.77% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are larger than Roche Holding AG quarterly revenues of --. Alcon's net income of $350M is higher than Roche Holding AG's net income of --. Notably, Alcon's price-to-earnings ratio is 38.31x while Roche Holding AG's PE ratio is 28.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.32x versus 3.79x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Sandoz Group AG has a net margin of 14.15% compared to Alcon's net margin of -39.83%. Alcon's return on equity of 5.25% beat Sandoz Group AG's return on equity of --.

Alcon has a consensus price target of $105.79, signalling upside risk potential of 22.73%. On the other hand Sandoz Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Alcon has higher upside potential than Sandoz Group AG, analysts believe Alcon is more attractive than Sandoz Group AG.

Alcon has a beta of 0.948, which suggesting that the stock is 5.206% less volatile than S&P 500. In comparison Sandoz Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alcon has a quarterly dividend of $0.34 per share corresponding to a yield of 0.4%. Sandoz Group AG offers a yield of 1.38% to investors and pays a quarterly dividend of $0.73 per share. Alcon pays 12.77% of its earnings as a dividend. Sandoz Group AG pays out -- of its earnings as a dividend. Alcon's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are larger than Sandoz Group AG quarterly revenues of $74.4M. Alcon's net income of $350M is higher than Sandoz Group AG's net income of -$29.6M. Notably, Alcon's price-to-earnings ratio is 38.31x while Sandoz Group AG's PE ratio is 26.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.32x versus 2.20x for Sandoz Group AG. Usually stocks with elevated PS ratios are considered overvalued.